How to Verify FDA-Approved Amoxicillin Products

What Does FDA Approval Mean for an Amoxicillin Product?

FDA approval means that a specific drug product has been evaluated and approved under an applicable U.S. drug application pathway. The approval covers defined characteristics, including the active ingredient, dosage form, strength, route of administration and approved labeling. It is not simply an endorsement of an ingredient name. Different finished products containing amoxicillin may be associated with different applications and product records.

For an original drug application, FDA evaluates the information supporting the product's safety and effectiveness for its approved uses. An approved generic drug ordinarily relies on the abbreviated new drug application pathway, which requires the product to meet applicable standards for pharmaceutical equivalence, bioequivalence, quality and labeling relative to its reference product. The precise regulatory requirements depend on the application and product characteristics.

Approval also does not mean that a medicine is appropriate for every patient or infection. Human oral amoxicillin remains prescription-only, and its FDA-approved labeling addresses indications, contraindications, warnings and administration requirements. A healthcare professional must determine whether antibacterial treatment is clinically indicated. The amoxicillin prescription-status guide explains why FDA approval does not create an over-the-counter purchasing option.

For verification purposes, the relevant question is not merely whether amoxicillin is an FDA-approved ingredient. It is whether the specific product being investigated corresponds to an effective FDA approval and whether its claimed formulation and strength match the regulatory record.

What Is the FDA Orange Book, and What Information Does It Contain?

The FDA Orange Book is the principal public reference for identifying many FDA-approved human drug products regulated through the New Drug Application and Abbreviated New Drug Application pathways. Its official name is Approved Drug Products with Therapeutic Equivalence Evaluations. The database groups products by active ingredient and pharmaceutical characteristics, then provides regulatory information about the applications and individual products associated with those records.

An Orange Book search can show the drug's trade name, applicant, dosage form, administration route, strength, application number, product number, approval date and relevant therapeutic equivalence classification. It can also identify reference listed drugs and reference standards when applicable. The database contains regulatory status information that helps distinguish products in the active prescription drug list from products appearing in the discontinued drug product list.

The Orange Book serves a different purpose from a pharmacy catalog. It does not provide reliable real-time retail inventory, individual insurance copays, delivery promises or consumer purchase instructions. A product may have an FDA approval record while being unavailable through a particular dispensing pharmacy. Conversely, a pharmacy inventory listing is not sufficient evidence of an FDA approval.

The FDA provides searchable Orange Book information and downloadable data files. The electronic database receives ongoing updates, while downloadable product files are updated on a monthly schedule. Therefore, a regulatory claim about a specific product's current status should be checked against the relevant live record rather than inferred from an undated spreadsheet or historical screenshot.

How to Search the Orange Book for Amoxicillin

Begin with the active ingredient. In the FDA's electronic Orange Book search, the ingredient name amoxicillin can be used to locate records associated with plain amoxicillin products. The ingredient search is generally more comprehensive than searching only a historical trade name because approved generic products may appear under different trade names and applicants.

Next, review the dosage form and route groupings. A search may return capsules, conventional tablets, chewable tablets and preparations for oral suspension as separate categories. Those categories matter because approval and therapeutic equivalence are evaluated at the product level. A capsule record should not automatically be interpreted as applying to a tablet merely because the strength number is the same.

Then examine the individual product's strength, application number, product number, applicant and current Orange Book classification. Where therapeutic equivalence information is available, the appropriate code should be interpreted within the relevant pharmaceutical-equivalence grouping. If the search result is ambiguous, the application and product identifiers provide a more precise route to the corresponding FDA record.

Finally, determine whether the record appears in the active or discontinued portion of the Orange Book. A product in the discontinued section may retain an approved regulatory history even though it is not currently marketed. The database should be read as an approval and equivalence resource, not as a guarantee that any listed item can be dispensed immediately.

NDA vs ANDA: How FDA Approval Pathways Differ

An New Drug Application (NDA) is a regulatory application pathway through which FDA evaluates information supporting a drug product's safety and effectiveness. Original branded products are commonly associated with NDAs, although the NDA category also includes applications submitted through pathways such as section 505(b)(2). An NDA record should not automatically be interpreted as proof that the product is currently marketed under a particular brand name.

An Abbreviated New Drug Application (ANDA) is the principal approval pathway for generic prescription drug products. Instead of independently repeating the complete clinical development program of the original product, an ANDA generally relies on the FDA's previous finding of safety and effectiveness for a reference listed drug and must meet applicable equivalence and quality requirements. Once approved, an ANDA provides regulatory authorization for the generic drug product described in that application.

The two application types should not be treated as a simple ranking of medicine quality. FDA-approved generics must meet the applicable approval standards, and the abbreviated pathway is designed to avoid unnecessary duplication of evidence while maintaining requirements for pharmaceutical quality and therapeutic performance. Whether two particular products are therapeutically equivalent should be checked through the relevant FDA evaluation rather than inferred from the terms brand or generic alone.

In the Orange Book data files, application type is represented by N for NDA and A for ANDA. The application number identifies the broader regulatory submission, while a separate product number identifies an individual approved product within that application. These identifiers provide a more reliable basis for verification than a manufacturer name copied from an online pharmacy listing.

How to Read an FDA Amoxicillin Approval Record

Orange Book product records use a defined set of fields. Understanding them helps readers distinguish a regulatory approval from product packaging, commercial distribution and general drug labeling. For example, an application can contain multiple approved strengths, while each strength may have its own FDA product number. The applicant is the entity legally responsible for the application and should not automatically be equated with the physical manufacturer of every distributed package.

The field definitions below follow the FDA's published Orange Book data documentation. They explain the structure of the official records without inventing application numbers, approval dates or therapeutic equivalence ratings for individual amoxicillin products.

Which Amoxicillin Dosage Forms and Strengths Appear in U.S. Product Records?

U.S. amoxicillin labeling documents several oral dosage forms, including capsules, conventional tablets, chewable tablets and powder for oral suspension. These presentations differ in their finished product characteristics and the way strength is expressed. The regulatory search should be performed for the exact dosage form rather than assuming that a record for one form covers the others.

The following examples are supported by U.S. amoxicillin labeling records available through DailyMed. They illustrate established labeled product presentations, not a certified inventory of every currently marketed or currently active Orange Book entry. The current approval and marketing classification of an individual product must still be confirmed through its FDA application record.

Selected FDA Amoxicillin NDA and ANDA Product Records

Real FDA application numbers make the distinction between a drug name and a specifically approved product concrete. The FDA supplemental approval letter dated May 1, 2024 identifies four existing Amoxil NDAs: 050542, 050754, 050760 and 050761. That letter approved safety-related labeling supplements; it did not represent the original approval of all four product families on that date. Historical FDA Orange Book entries provide the individual strength and product-number associations illustrated below.

Generic examples can be checked using FDA Orange Book product records and dated cumulative supplements. In the August 2026 cumulative supplement, ANDA 061926 is associated with 250 mg and 500 mg capsules, ANDA 064013 with 125 mg and 250 mg chewable tablets, and ANDA 065056 with 500 mg and 875 mg conventional tablets. The August entries reflect changes to applicant names for these established applications, not new initial approvals.

These seven examples illustrate the application-to-product relationship; they are not an exhaustive catalog or a real-time statement of marketing status. Product numbers identify specific approved presentations within an application, while a later supplement or applicant change can affect the administrative record without creating a new drug product. Before publishing a present-tense assertion about an individual entry being actively marketed, check the current Orange Book classification separately and confirm actual supply with the dispensing pharmacy.

Amoxicillin Capsules and Conventional Tablets Are Separate FDA Products

Amoxicillin capsules and conventional tablets can contain the same active ingredient and may share a nominal strength. Nevertheless, dosage form is an essential component of pharmaceutical identity. A 500 mg capsule and a 500 mg conventional tablet are not the same finished dosage form, even though both are labeled with 500 mg of amoxicillin. Their approval records and therapeutic equivalence groupings should therefore be checked separately.

FDA labeling commonly describes conventional amoxicillin capsules in 250 mg and 500 mg strengths and conventional tablets in 500 mg and 875 mg strengths. The amoxicillin capsule guide and amoxicillin tablet guide provide the form-specific product context. The regulatory question on this page is whether a particular product's strength and dosage form correspond to its FDA application.

Different appearance, scoring, packaging or inactive ingredients do not automatically establish that two appropriately approved generic products are therapeutically inequivalent. Those characteristics must be interpreted alongside pharmaceutical-equivalence requirements and the relevant FDA product data. Conversely, the presence of the same active ingredient does not authorize switching from a capsule to a tablet or changing the prescribed strength without appropriate professional authorization.

When comparing entries, use the complete product identification rather than a single strength number. A product approved as a conventional tablet should not be presented as evidence that a chewable product or a capsule from another applicant has the same approval record.

How to Verify FDA Records for Amoxicillin Chewable Tablets

Chewable amoxicillin tablets represent a separate oral dosage form. U.S. labeling records include historical presentations with strengths such as 125 mg, 200 mg, 250 mg and 400 mg. These should be understood as labeled product examples rather than proof that every strength is currently available through U.S. pharmacies. A current Orange Book search is needed to establish which corresponding approval records are in the active or discontinued sections.

The amoxicillin chewable tablet guide addresses the dosage form and its product characteristics. From a regulatory perspective, the principal distinction is that chewable tablets have their own formulation specifications and should not be grouped with conventional swallowed tablets solely because both are solid oral products.

Inactive ingredients can also differ among chewable products and between different labeling records. Some chewable formulations contain aspartame, a source of phenylalanine. Such ingredient information belongs to product-specific labeling, not to the strength field of the Orange Book. A person evaluating a formulation-related safety concern should review the actual labeling and consult a healthcare professional rather than infer ingredient composition from the FDA application number.

A historical chewable product may remain relevant to an approval-history search even after commercial distribution ends. This is an example of why a regulatory catalog should preserve the distinction between an approved product record and an actively supplied retail product.

Amoxicillin Oral Suspension: Concentration, Powder and Bottle Volume

Amoxicillin oral suspension is commonly supplied to pharmacies as powder intended for reconstitution. U.S. product labeling identifies concentrations such as 125 mg/5 mL, 200 mg/5 mL, 250 mg/5 mL and 400 mg/5 mL after preparation. These concentrations describe the amount of amoxicillin in a measured volume of the finished suspension. They are not equivalent to the total amount of drug in a manufacturer's bottle.

This difference matters when reading approval records. FDA product-strength fields identify the potency associated with the approved product, while the container or package may separately specify a final prepared volume. The amount of water used in preparation is another product-specific labeling detail. A 100 mL final bottle volume should not be confused with an instruction to add 100 mL of water, and the precise preparation directions must be obtained from the product's actual labeling.

The amoxicillin suspension guide explains the formulation and preparation distinctions. A regulatory search can identify a matching concentration and dosage form, but it does not establish that a particular pharmacy stocks a given bottle size or has prepared a suspension for dispensing.

An approved oral suspension product also remains subject to prescription and handling requirements. The pharmacist must identify the actual supplied preparation and follow the applicable instructions for reconstitution, storage and the period after which unused medicine should be discarded. FDA approval is not a substitute for verifying those details on the specific dispensed product.

RLD, Reference Standard and Therapeutic Equivalence Codes Explained

A Reference Listed Drug (RLD) is an approved drug product identified by FDA as the product upon which an applicant relies in seeking approval of an ANDA. The RLD provides the regulatory reference for the generic application. This designation is not the same as a statement that the product is currently available at every pharmacy or that it is always the least expensive version of the medicine.

A Reference Standard (RS) is the drug product selected by FDA for use in the in-vivo bioequivalence testing required for a particular generic application. The reference standard often is the RLD, but the two designations can differ. For example, FDA may select an appropriate reference standard when the relevant RLD is no longer commercially available. The distinction matters when interpreting older approval records and products in the discontinued section.

Therapeutic equivalence codes provide another layer of information. FDA generally assigns an A-prefixed classification when it considers a product therapeutically equivalent to other pharmaceutically equivalent products, with AB and related numbered AB codes used in relevant bioequivalence contexts. A B-prefixed code indicates that therapeutic equivalence has not been established under the applicable FDA criteria. The specific meaning depends on the code and product grouping.

An AB designation is not a universal interchangeability label covering every medicine containing amoxicillin. Therapeutic equivalence is evaluated among pharmaceutical equivalents, taking account of the active ingredient, dosage form, route, strength and other applicable criteria. A generic amoxicillin capsule cannot automatically be treated as therapeutically equivalent to an oral suspension or an amoxicillin/clavulanate tablet merely because the same ingredient name appears in the product description.

The Orange Book provides regulatory equivalence information, but practical dispensing and substitution remain subject to the prescription and applicable state law. Patients should not independently change the dosage form, strength or product based on a TE code without professional guidance.

FDA Approved Does Not Necessarily Mean Currently Marketed

One of the most important distinctions in FDA regulatory records is the difference between approval status and commercial marketing status. An approved drug product may remain in the regulatory system after its manufacturer or applicant stops distributing it. FDA's Orange Book includes a discontinued drug product list containing multiple categories of products that are not presently marketed in the ordinary way.

The discontinued list can include approved products that were never marketed, products whose commercial distribution ended, products associated with export-only arrangements and certain other categories. Inclusion in this section does not by itself establish that the product was withdrawn because it was unsafe or ineffective. FDA separately addresses whether a product has been withdrawn from sale for safety or effectiveness reasons, and that regulatory conclusion should not be inferred solely from the word discontinued.

The distinction is also relevant when reviewing historical amoxicillin brands or formulations. A product may have an NDA or ANDA record and a documented approval date while being absent from current retail distribution. The regulatory record can still be useful for understanding the approval history or the reference relationship of generic products, but it should not be represented as evidence of current pharmacy stock.

Even a product appearing in the active Orange Book section should not be treated as a guaranteed retail offering. Published regulatory information and commercial supply data serve different purposes and may be updated at different times. Actual distribution and pharmacy-level availability require separate verification.

FDA Approval, Tentative Approval and Withdrawal Are Different Regulatory Events

An effective FDA approval should not be confused with a tentative approval. A tentative approval can indicate that a proposed drug application has met relevant substantive approval requirements but cannot receive final approval at that time because of an applicable legal or regulatory barrier, such as an exclusivity restriction. Tentative approval is not authorization to commercially market the proposed product as an FDA-approved drug.

FDA's Orange Book does not ordinarily list tentatively approved products as finally approved products. A company announcement describing a successful generic review therefore requires careful reading. The statement that an ANDA has been accepted for review, tentatively approved or finally approved represents three different regulatory statuses.

Withdrawal of approval is another separate event. An application can be withdrawn for reasons that do not involve safety or effectiveness, while some regulatory actions specifically concern safety or effectiveness findings. The reason and legal status should be confirmed from FDA records rather than inferred from a product's absence from pharmacy catalogs or from its appearance in a discontinued list.

For a trustworthy product catalog, historical regulatory events should retain their correct meanings. An application being approved at one point in time does not establish that it remains effective indefinitely, and a product's discontinuation from marketing does not automatically establish that the original approval was unsafe.

FDA Orange Book vs DailyMed: Which Database Answers Which Question?

The Orange Book and DailyMed are complementary resources, but they answer different questions. The Orange Book identifies FDA approval records and therapeutic equivalence evaluations. DailyMed, operated by the U.S. National Library of Medicine, provides current and historical drug-labeling information submitted through the Structured Product Labeling system. Its records can describe ingredients, strengths, dosage forms, packaging and prescribing information.

DailyMed is particularly useful when a researcher needs to understand what the label says about a formulation. For example, a labeling record may explain that an amoxicillin oral suspension contains a specified amount of active ingredient per 5 mL after reconstitution. It may also identify storage requirements, inactive ingredients and package configurations. These details extend beyond the limited fields displayed in an Orange Book product record.

However, the presence of a label on DailyMed does not independently establish FDA approval. FDA labeling resources include information submitted by companies, and submitted labeling may not always match the last FDA-approved labeling or the exact product currently distributed. For definitive approval verification, the relevant FDA application record should be checked through Orange Book or Drugs@FDA.

A rigorous product-identification process therefore uses the Orange Book for regulatory approval and equivalence, Drugs@FDA when application history or FDA-approved labeling is needed, and DailyMed for detailed submitted product labeling. The results should be reconciled using product identifiers and formulation characteristics rather than assuming that every database entry refers to the same marketed package.

Why an NDC Number Is Not Proof of FDA Approval

The National Drug Code (NDC) is an identifier used in U.S. drug listing and product distribution. It can help distinguish a labeler, a drug product and a particular package configuration. The NDC is useful for pharmacy inventory systems, claims processing and identifying which commercial package is being discussed. It is not the same as an FDA NDA or ANDA application number.

FDA explicitly states that assignment of an NDC does not establish that the associated medicine is FDA-approved. The NDC Directory contains information submitted by labelers, and inclusion does not mean that FDA has independently verified every statement in the listing. The directory can include products whose marketing status differs from the status of approved NDA or ANDA products.

The distinction is particularly important when evaluating internet pharmacy advertisements. A seller may display an NDC to make a listing appear official. That identifier may help identify the claimed product, but it does not prove that the advertised item is authentic, that the seller is licensed or that the product corresponds to an effective FDA approval. The amoxicillin product authenticity guide explains additional checks relevant to identifying the actual dispensed medication.

Package differences provide another example. Multiple NDC package records can relate to the same approved drug product or a particular commercial labeler arrangement. An FDA application and product number identify the approval at a different regulatory level. These identifiers should be matched carefully rather than counted as separate FDA approvals simply because a product appears in several bottle sizes.

FDA Applicant, Manufacturer, Distributor and Labeler Are Not Always the Same

An Orange Book applicant is the organization legally responsible for the relevant FDA drug application. The applicant may be associated with a manufacturer, but that relationship should not be assumed solely from the applicant field. Finished drug production, packaging, repackaging, relabeling and distribution can involve different companies under applicable regulatory arrangements.

A product's NDC labeler is also not necessarily the holder of the original NDA or ANDA. FDA drug listing rules permit different kinds of firms to appear as labelers, including manufacturers, repackagers and relabelers. This explains why a pharmacy product database may display a company name that differs from the applicant shown in the Orange Book. The difference is not automatically evidence that the product is unapproved, but it does require accurate interpretation.

The amoxicillin generic manufacturers guide covers the separate question of identifying companies and their roles in the U.S. supply chain. This regulatory page is concerned with approval responsibility, not ranking manufacturers or promising that a listed company is currently supplying a particular pharmacy.

Another important exception is the authorized generic. FDA describes an authorized generic as a product marketed under the brand product's existing NDA without using the brand name on its labeling. It may therefore lack a separate ANDA entry even though it is lawfully marketed under the applicable NDA. The absence of a stand-alone generic application should not automatically be treated as evidence that such a product is unapproved.

FDA Records for Plain Amoxicillin Are Separate From Amoxicillin/Clavulanate

Plain amoxicillin and amoxicillin/clavulanate have different active-ingredient identities. Plain amoxicillin contains amoxicillin, while the combination includes amoxicillin together with clavulanate. The distinction is reflected in FDA product records, prescribing information and application histories. A search for amoxicillin-containing products may encounter both categories, but they should not be combined into one regulatory product family.

The strength field can make the distinction especially important. A conventional plain amoxicillin tablet labeled 875 mg is not the same product as an amoxicillin/clavulanate tablet containing 875 mg amoxicillin plus 125 mg clavulanate. The combination specifies two active ingredients, and its strength information must be interpreted accordingly. Neither product is an automatic substitute for the other.

Augmentin is a branded amoxicillin/clavulanate product family with distinct conventional immediate-release formulations, Augmentin XR extended-release tablets and Augmentin ES-600 oral suspension. These products have their own regulatory records and labeling characteristics. The Augmentin FDA-approved products guide addresses the separate approval and formulation questions for these combinations.

The amoxicillin/clavulanate overview explains the ingredient distinction in more detail. For regulatory verification, the rule is straightforward: identify the exact active ingredient or ingredient combination first, then match the dosage form, strength and application record. Similar brand names or overlapping strengths do not establish pharmaceutical equivalence.

Four Practical Examples of Amoxicillin FDA Record Verification

Scenario 1: A pharmacy listing advertises generic amoxicillin 500 mg. The strength alone does not identify the finished product. It may refer to a capsule or conventional tablet. A regulatory check should establish the dosage form and compare the relevant approval record before interpreting the item as a specific FDA-approved product.

Scenario 2: A historical label describes a chewable amoxicillin strength. The researcher finds the strength in an older DailyMed record. That confirms the content of the historical labeling document, but it does not independently establish that the associated product is currently marketed. The corresponding Orange Book record should be checked for application information and regulatory status.

Scenario 3: A product appears in the Orange Book discontinued section. The listing may represent an approved product that is no longer marketed. The researcher should not automatically call it withdrawn for safety reasons or promise that it is available for prescription dispensing. Any specific FDA determination about withdrawal reasons must be verified separately.

Scenario 4: An online seller provides an NDC but no clear application record. The NDC may identify a claimed listed product or package, but it is not proof of FDA approval. The relevant application, labeling and product identity should be verified using appropriate FDA resources. Even when the product's approval is confirmed, the seller's legitimacy and the authenticity of the actual shipment remain separate questions.

Final Checklist for Verifying FDA-Approved Amoxicillin Products

Step 1: Identify the active ingredient. Establish whether the product contains plain amoxicillin or a combination such as amoxicillin/clavulanate. Do not rely on a shortened brand name, partial strength description or pharmacy search snippet when the complete ingredient identity is available.

Step 2: Match the pharmaceutical product. Check the dosage form, oral route, strength and relevant product description. For liquid products, distinguish the concentration after reconstitution from the final prepared bottle volume. For tablets and capsules, do not assume that matching milligram strengths establish identical regulatory products.

Step 3: Verify the FDA application. Use the Orange Book to locate the appropriate NDA or ANDA record and its application and product numbers. Review any applicable RLD, RS or therapeutic equivalence information. Use Drugs@FDA if additional application history or the FDA-approved labeling record is required.

Step 4: Interpret marketing and packaging separately. Determine whether the product appears in the active or discontinued Orange Book section, then use appropriate labeling and listing resources for further product identification. An NDC, historical brand name or approval date does not independently confirm current pharmacy inventory or commercial distribution.

Step 5: Keep regulatory approval separate from medical access. FDA-approved oral amoxicillin remains prescription-only. A valid application record does not establish that a pharmacy can dispense the product without a prescription, that insurance will cover it or that the medicine is appropriate for a particular illness. A clinician and dispensing pharmacist remain responsible for the relevant medical and medication-safety decisions.

The central verification principle is that FDA approval belongs to a defined drug product and application record, while marketing status, NDC identification and retail availability describe different aspects of that product's life cycle. Keeping those concepts separate makes amoxicillin regulatory research more accurate and reduces misleading claims about supposedly approved or available medications.